Long Term Experience With Abatacept in Routine Clinical Practice

Trial Profile

Long Term Experience With Abatacept in Routine Clinical Practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ACTION
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 16 Jun 2018 Results (n=135) assessing up to 5-year retention of abatacept in belgian patients with moderate-to-severe rheumatoid-arthritis, were presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 08 Nov 2017 Results assessing biologic naive and DMARD use prior to initiation and after discontinuation of abatacept overall and by treatment line, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 08 Nov 2017 Results (n=2350) assessing retention rate presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top